# US 2021/0079485 A1 · Detecting babesia species nucleic acid in a sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079485 A1
- Document ID: US20210079485A1
- Status: Published application
- Kind: A1
- Application number: 16/611,806
- Filed: 2018-06-06
- Published: 2021-03-18
- Earliest claimed: 2017-06-07
- Assignees: Gen-Probe Incorporated
- Applicants: Gen-Probe Incorporated
- Inventors: Vanessa Bres; Deanna Self; Jeffrey M. Linnen
- Web page: https://patentgrep.com/patent/US20210079485A1

## CPC

- C12Q 1/6893: for protozoa
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

There is described herein a method for specifically detecting Babesia species nucleic acid in a sample, which in one aspect comprises: (1) contacting a sample, said sample suspected of containing Babesia species nucleic acid, with at least two oligomers for amplifying a target region of a Babesia species target nucleic acid, wherein the at least two amplification oligomers comprise: (a) a first amplification oligomer comprising a first target-hybridizing sequence (i) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:66 and comprises SEQ ID NO:56 or 57; or (ii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:96 and comprises SEQ ID NO:101; or (iii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:97 and comprises SEQ ID NO:101; (iv) comprises or consists of SEQ ID NO:8; (v) comprises or consists of SEQ ID NO:83 and (b) a second amplification oligomer comprising a second target-hybridizing sequence that is from about 15 to about 33 contiguous nucleotides in length, and (i) is contained in SEQ ID NO:68 and comprises SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, or SEQ ID NO:85; or (ii) is contained in SEQ ID NO:67 and comprises SEQ ID NO:45 or SEQ ID NO:52; or (iii) is contained in SEQ ID NO:70 and comprises SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, or SEQ ID NO:51; (2) performing an in vitro nucleic acid amplification reaction, wherein any Babesia target nucleic acid present in said sample is used as a template for generating an amplification product; and (3) detecting the presence or absence of the amplification product, thereby indicating the presence or absence of Babesia species target nucleic acid in said sample.

## Claims

### Claim 1

A method for specifically detecting Babesia species nucleic acid in a sample, said method comprising:
(1) contacting a sample, said sample suspected of containing Babesia species nucleic acid, with at least two oligomers for amplifying a target region of a Babesia species target nucleic acid, wherein the at least two amplification oligomers comprise:
(a) a first amplification oligomer comprising a first target-hybridizing sequence
(i) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:66 and comprises SEQ ID NO:56 or 57;
(ii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:96 and comprises SEQ ID NO:101;
(iii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:97 and comprises SEQ ID NO:101;
(iv) comprises or consists of SEQ ID NO:8; or
(v) comprises or consists of SEQ ID NO:83; and
(b) a second amplification oligomer comprising a second target-hybridizing sequence that is from about 15 to about 33 contiguous nucleotides in length, and
(i) is contained in SEQ ID NO:68 and comprises SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, or SEQ ID NO:85; or
(ii) is contained in SEQ ID NO:67 and comprises SEQ ID NO:45 or SEQ ID NO:52;
(iii) is contained in SEQ ID NO:70 and comprises SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, or SEQ ID NO:51; or
(iv) comprises or consists of SEQ ID NO:84:,
(2) performing an in vitro nucleic acid amplification reaction, wherein any Babesia target nucleic acid present in said sample is used as a template for generating an amplification product; and
(3) detecting the presence or absence of the amplification product, thereby indicating the presence or absence of Babesia species target nucleic acid in said sample.

### Claim at position 2

2-77. (canceled)

### Claim 78

A combination of at least two oligomers for determining the presence or absence of Babesia in a sample, said oligomer combination comprising first and second amplification oligomers for amplifying a target region of Babesia target nucleic acid, wherein
(a) the first amplification oligomer comprises a first target-hybridizing sequence (i) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:66 and comprises SEQ ID NO:56 or 57; or (ii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:96 and comprises SEQ ID NO:101; or (iii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:97 and comprises SEQ ID NO:101; (iv) comprises or consists of SEQ ID NO:8; (v) comprises or consists of SEQ ID NO:83; and
(b) the second amplification oligomer comprises a second target-hybridizing sequence that is from about 15 to about 33 contiguous nucleotides in length, and
(i) is contained in SEQ ID NO:68 and comprises SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, or SEQ ID NO:85; or
(ii) is contained in SEQ ID NO:67 and comprises SEQ ID NO:45 or SEQ ID NO:52;
(iii) is contained in SEQ ID NO:70 and comprises SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, or SEQ ID NO:51; or
(iv) comprises or consists of SEQ ID NO:84.

### Claim 79 (depends on 78)

The combination of claim 78, wherein the first amplification comprises or consists of the sequence selected from the group consisting of: SEQ ID NOs:2 and 4 and 6 and 8 and 83.

### Claim 80 (depends on 78)

The combination of claim 78, wherein the second amplification oligomer comprises or consists of the sequence selected from the group consisting of: SEQ ID NOs:13, 16, 17, 18, 19, 20, 21, 27, 28, 29, 31, 32, 33, 34, 35, 36, 84 and 86.

### Claim 81

(canceled)

### Claim 82 (depends on 78)

The combination of claim 78, wherein the first amplification oligomer is a promoter primer or promoter provider further comprising a promoter sequence located 5′ to the first target-hybridizing sequence.

### Claim 83 (depends on 82)

The combination of claim 82, wherein the promoter sequence is a T7 promoter sequence.

### Claim 84

(canceled)

### Claim 85 (depends on 83)

The combination of claim 83, wherein the first amplification oligomer comprises or consists of a sequence selected from the group consisting of SEQ ID NOs:1 and 3 and 5 and 7 and 82.

### Claim 86 (depends on 78)

The combination of claim 78, wherein the first and second target-hybridizing sequences respectively comprise or consist of the nucleotide sequences of:
(a) SEQ ID NO:2 or 6 and SEQ ID NO:11;
(b) SEQ ID NO:4 or 6 and SEQ ID NO:13;
(c) SEQ ID NO:4 and SEQ ID NO:16 or SEQ ID NO:17;
(d) SEQ ID NO:4 and SEQ ID NO:18 or SEQ ID NO:19;
(e) SEQ ID NO:4 and SEQ ID NO:20;
(f) SEQ ID NO:4 or 6 or 8 and SEQ ID NO:21;
(g) SEQ ID NO:2 or 4 or 8 and SEQ ID NO:27;
(h) SEQ ID NO:4 and SEQ ID NO:28;
(i) SEQ ID NO:4 and SEQ ID NO:29;
(j) SEQ ID NO:4 and SEQ ID NO:31;
(k) SEQ ID NO:8 and SEQ ID NO:32;
(l) SEQ ID NO:8 and SEQ ID NO:33;
(m) SEQ ID NO:8 and SEQ ID NO:34;
(n) SEQ ID NO:8 and SEQ ID NO:35;
(o) SEQ ID NO:8 and SEQ ID NO:36;
(p) SEQ ID NO:8 and SEQ ID NO:84;
(q) SEQ ID NO:8 and SEQ ID NO:86;
(r) SEQ ID NO:83 and SEQ ID NO:32;
(s) SEQ ID NO:83 and SEQ ID NO:33;
(t) SEQ ID NO:83 and SEQ ID NO:34;
(u) SEQ ID NO:83 and SEQ ID NO:35;
(v) SEQ ID NO:83 and SEQ ID NO:36;
(w) SEQ ID NO:83 and SEQ ID NO:84; or
(x) SEQ ID NO:83 and SEQ ID NO:86.

### Claim 87

(canceled)

### Claim 88 (depends on 78)

The combination of claim 78, further comprising at least one capture probe oligomer, wherein the at least one capture probe oligomer comprises a target-hybridizing sequence covalently attached to a sequence or moiety that binds to an immobilized probe, wherein said target-hybridizing sequence (i) is from about 15 to about 21 contiguous nucleotides contained in the sequence of SEQ ID NO:78, or (ii) is about 21 to 30 contiguous nucleotides comprising the sequence of SEQ ID NO:78; or (iii) the sequence consists of SEQ ID NO:44.

### Claim 89

(canceled)

### Claim 90 (depends on 88)

The combination of claim 88, wherein the capture probe oligomer sequence comprises or consists of SEQ ID NO:43.

### Claim 91 (depends on 78)

The combination of claim 78, further comprising a detection probe oligomer, wherein the detection probe oligomer comprises a target-hybridizing sequence that is from about 14 to about 40 nucleotides in length and is configured to specifically hybridize to a target sequence contained in SEQ ID NO:59, the RNA equivalent of SEQ ID NO:59, the complement of SEQ ID NO:59, the RNA equivalent of the complement of SEQ ID NO:59, SEQ ID NO:65, the DNA equivalent of SEQ ID NO:65, the complement of SEQ ID NO:65, or the DNA equivalent of the complement of SEQ ID NO:65.

### Claim 92

(canceled)

### Claim 93 (depends on 91)

The combination of claim 91, wherein the detection probe target-hybridizing sequence (i) is contained in the sequence of SEQ ID NO:59 and includes at least the sequence of SEQ ID NO:42, 92, 94, or 99, or (ii) is contained in the sequence of SEQ ID NO:65 and includes at least the sequence of SEQ ID NO:59, 60, 94 or 99.

### Claim 94

(canceled)

### Claim 95 (depends on 91)

The combination of claim 91, wherein the detection probe target-hybridizing sequence consists of the sequence selected from the group consisting of: SEQ ID NO:37, 38, 39, 40, 41, 42, 59, 60, 91, 92, 93, 94, 98 or 99.

### Claim at position 21

96-98. (canceled)

### Claim 99 (depends on 88)

The combination of claim 88, wherein the detection probe oligomer further comprises a 2′ methoxy modification on at least one of a nucleotide residue member of the nucleotide sequence.

### Claim 100 (depends on 88)

The combination of claim 88, wherein the first and second amplification oligomer target-hybridizing sequences and the detection probe oligomer target-hybridizing sequences respectively comprise or consist of the nucleotide sequences of:
(a) SEQ ID NO:2 and SEQ ID NO:11 and SEQ ID NO:39 or SEQ ID NO:37;
(b) SEQ ID NO:2 and SEQ ID NO:27 and SEQ ID NO:38 or SEQ ID NO:39;
(c) SEQ ID NO:4 and SEQ ID NO:13 and SEQ ID NO:39 or SEQ ID NO:37;
(d) SEQ ID NO:4 and SEQ ID NO:16 or SEQ ID NO:17 and SEQ ID NO:39;
(e) SEQ ID NO:4 and SEQ ID NO:18 or SEQ ID NO:19 and SEQ ID NO:39 or SEQ ID NO:37;
(f) SEQ ID NO:4 and SEQ ID NO:20 and SEQ ID NO:39 or SEQ ID NO:37;
(g) SEQ ID NO:4 and SEQ ID NO:21 and SEQ ID NO:39 or SEQ ID NO:37;
(h) SEQ ID NO:4 and SEQ ID NO:27 and SEQ ID NO:39 or SEQ ID NO:38;
(i) SEQ ID NO:4 and SEQ ID NO:28 and SEQ ID NO:39;
(j) SEQ ID NO:4 and SEQ ID NO:29 and SEQ ID NO:39 or SEQ ID NO:37;
(k) SEQ ID NO:4 and SEQ ID NO:31 and SEQ ID NO:39;
(l) SEQ ID NO:6 and SEQ ID NO:11 and SEQ ID NO:37;
(m) SEQ ID NO:6 and SEQ ID NO:13 and SEQ ID NO:37;
(n) SEQ ID NO:6 and SEQ ID NO:21 and SEQ ID NO:37;
(o) SEQ ID NO:8 and SEQ ID NO:21 and SEQ ID NO:39 or SEQ ID NO:37 or SEQ ID NO:42;
(p) SEQ ID NO:8 and SEQ ID NO:27 and SEQ ID NO:39;
(q) SEQ ID NO:8 and SEQ ID NO:32 and SEQ ID NO:37, 42, 91, 92, or 93;
(r) SEQ ID NO:8 and SEQ ID NO:33 and SEQ ID NO:37, 42, 91, 92, or 93;
(s) SEQ ID NO:8 and SEQ ID NO:34 and SEQ ID NO:37, 42, 91, 92, or 93;
(t) SEQ ID NO:8 and SEQ ID NO:35 and SEQ ID NO:37, 42, 91, 92, or 93;
(u) SEQ ID NO:8 and SEQ ID NO:36 and SEQ ID NO:37, 42, 91, 92, or 93;
(v). SEQ ID NO:8 and SEQ ID NO:84 and SEQ ID NO:37, 42, 91, 92, or 93;
(w) SEQ ID NO:8 and SEQ ID NO:86 and SEQ ID NO:37, 42, 91, 92, or 93;
(x) SEQ ID NO:83 and SEQ ID NO:21 and SEQ ID NO:39 or SEQ ID NO:37 or SEQ ID NO:42;
(y) SEQ ID NO:83 and SEQ ID NO:27 and SEQ ID NO:39;
(z) SEQ ID NO:83 and SEQ ID NO:32 and SEQ ID NO:37, 42, 91, 92, or 93;
(aa) SEQ ID NO:83 and SEQ ID NO:33 and SEQ ID NO:37, 42, 91, 92, or 93;
(ab) SEQ ID NO:83 and SEQ ID NO:34 and SEQ ID NO:37, 42, 91, 92, or 93;
(ac) SEQ ID NO:83 and SEQ ID NO:35 and SEQ ID NO:37, 42, 91, 92, or 93;
(ad) SEQ ID NO:83 and SEQ ID NO:36 and SEQ ID NO:37, 42, 91, 92, or 93;
(ae). SEQ ID NO:83 and SEQ ID NO:84 and SEQ ID NO:37, 42, 91, 92, or 93;
(af) SEQ ID NO:83 and SEQ ID NO:86 and SEQ ID NO:37, 42, 91, 92, or 93; or
(ag) SEQ ID NO:8 or 83, SEQ ID NO:34, 84 or 86, and SEQ ID NO:37, 38, 39, 40, 41, 42, 59, 60, 91, 92, 93, 94, 98 or 99.

### Claim 101

(canceled)

### Claim 102 (depends on 91)

The combination of claim 91, wherein the detection probe further comprises a chemiluminescent label or a fluorescent label.

### Claim 103

(canceled)

### Claim 104 (depends on 91)

The combination of claim 91, wherein the detection probe further comprises a fluorescent label and a quencher.

### Claim at position 28

105-107. (canceled)

### Claim 108

A detection probe oligomer comprising:
(a) a target-hybridizing sequence that is from about 14 to about 40 nucleotides in length and is configured to specifically hybridize to a target sequence contained in SEQ ID NO:59, the RNA equivalent of SEQ ID NO:59, the complement of SEQ ID NO:59, the RNA equivalent of the complement of SEQ ID NO:59, SEQ ID NO:65, the DNA equivalent of SEQ ID NO:65, the complement of SEQ ID NO:65, or the DNA equivalent of the complement of SEQ ID NO:65; and
(b) a chemiluminescent label or a fluorescent label.

### Claim at position 30

109-123. (canceled)

### Claim 124 (depends on 78)

A kit comprising the combination of at least two oligomers according to claim 78.

### Claim 125 (depends on 78)

A reaction mixture comprising the combination of at least two oligomers according to claim 78.

### Claim at position 33

126-128. (canceled)
